Ainos, INC

Ainos, Inc. announced its second quarter 2026 financial results, revealing a substantial decrease in revenue and an increased net loss, while highlighting continued progress in its AI Nose technology deployments.

Ainos, Inc. announced the dismissal of YCM CPA INC. as its independent registered public accounting firm and the engagement of DLEE Accountancy, Inc. on July 9, 2026.

Ainos, Inc. has entered into a short-term unsecured credit facility agreement with CTBC Bank for NT$62,000,000, approximately US$1.94 million, to bolster its financial flexibility.

Ainos, Inc. announced its first quarter 2026 financial results, highlighting progress in AI Nose deployments across semiconductor and healthcare infrastructure markets, alongside a strategic financing arrangement.

Ainos, Inc. has entered into a three-year distribution agreement with Trusval Technology Co. Ltd. for its AINOS AI Nose and related products and services, including one-year exclusive rights for certain clients.

Ainos, Inc. announced its long-term platform strategy to digitize smell and establish scent as a native data language for artificial intelligence.

Ainos, Inc. reported a substantial decrease in revenue and a widening net loss for the second quarter of 2026, primarily due to a strategic shift away from VELDONA pet supplements towards its AI Nose platform, which is still in early commercialization stages.

Ainos reports a net loss of $2.46 million for Q1 2026 while advancing its AI Nose industrial commercialization strategy.

Ainos, Inc. reports increased revenue from its AI Nose platform and VELDONA pet supplements in Q3 2025, but faces continued net losses and significant liquidity challenges.

Ainos, Inc. reported increased net losses for Q2 and H1 2025, but secured a significant $2.1 million AI Nose order with ASE and regained Nasdaq minimum bid price compliance.

Ainos Inc. reports a 412% increase in revenue for Q1 2025, driven by VOC sensing product sales and strategic partnerships, while continuing to invest in AI-driven healthcare and technology.

Ainos Inc. reported a net loss for the third quarter of 2024, while continuing to invest in research and development, particularly in its AI Nose technology and VELDONA drug candidates.

Ainos, Inc. reports its fiscal year 2024 results, highlighting its strategic shift towards pipeline development, commercializing VELDONA Pet supplements, advancing clinical studies, and exploring strategic partnerships.

Ainos Inc. outlines a new voting agreement, financial performance, and strategic direction in its latest 10-K filing.

Ainos, Inc. Director Yao-Chung Chiang reported the acquisition of 3,500 common shares at $2.05 per share.

Director Yao-Chung Chiang acquired 2,000 shares of Ainos, Inc. common stock at a price of $2.13 per share.

Ainos, Inc. Director Yao-Chung Chiang reported the acquisition of 250 shares of common stock on May 28, 2026, at a price of $2.30 per share.

Director Yao-Chung Chiang acquired 2,000 shares of Ainos, Inc. common stock through his spouse on May 27, 2026.

Ainos, Inc. Director Ting-Chuan Lee sold 109,988 shares of common stock to cover tax obligations.

Taiwan Carbon Nano Technology Corp reported the sale of 41,000 shares of Ainos, Inc. common stock to cover tax obligations.

Ainos, Inc. announced its 2025 Annual Meeting of Stockholders to be held on November 7, 2025, to elect directors, ratify auditors, and approve a significant special stock award reservation.

Ainos, Inc. has announced that its Board of Directors and a majority shareholder have approved a reverse stock split, with a ratio between 1-for-2 and 1-for-5, to meet Nasdaq's minimum bid price requirement of $1.00 per share.

Ainos, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Ainos, Inc. will hold its 2024 Annual Meeting of Stockholders on September 27, 2024, to vote on the ratification of the appointment of KCCW Accountancy Corp. as its independent registered public accounting firm, approve the reservation of up to two million shares of common stock as special stock awards, and to transact such other business as may be properly brought before the Annual Meeting and any adjournments thereof.

Ainos, Inc. has filed a registration statement for the resale of up to 4,430,732 shares of its common stock by selling stockholders.

Reporting person Ting Chuan Lee has increased their beneficial ownership in Ainos, Inc. to 10.98% following a grant of 570,000 restricted stock units.

Chun-Jung Tsai filed an amendment to Schedule 13D reporting beneficial ownership of 686,999 shares of Ainos, Inc. common stock.

Ainos Inc. filed an amendment to its Schedule 13D disclosing changes in beneficial ownership following the vesting of restricted stock units.

ASE Technology Holding and ASE Test disclose a combined 8.4% beneficial ownership in Ainos, Inc. following recent convertible note and warrant agreements.

Ainos Inc. (Cayman Islands) filed Amendment 14 to its Schedule 13D, updating its beneficial ownership in Ainos, Inc. (Texas) to 6.76% and disclosing a minor share sale by TCNT.

Taiwan Carbon Nano Technology Corporation (TCNT) has reduced its stake in Ainos, Inc. to 13.62% and entered a voting agreement granting Ainos KY sole discretion over its voting shares.